Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER.

MLA

Koga, Kazuma, et al. “Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER.” Biological & Pharmaceutical Bulletin, vol. 47, no. 7, 2024, pp. 1296–300. EBSCOhost, https://doi.org/10.1248/bpb.b24-00130.

APA

Koga, K., Tasaka, Y., & Nawa, H. (2024). Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER. Biological & Pharmaceutical Bulletin, 47(7), 1296–1300. https://doi.org/10.1248/bpb.b24-00130

Chicago

Koga, Kazuma, Yuichi Tasaka, and Hideki Nawa. 2024. “Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER.” Biological & Pharmaceutical Bulletin 47 (7): 1296–1300. doi:10.1248/bpb.b24-00130.